Sanginita Chemicals Limited

NSEI:SANGINITA Stock Report

Market Cap: ₹388.5m

Sanginita Chemicals Future Growth

Future criteria checks 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Sanginita Chemicals zu prognostizieren.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Chemicals earnings growth19.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Revenues Working Against Sanginita Chemicals Limited's (NSE:SANGINITA) Share Price Following 26% Dive

Mar 11
Revenues Working Against Sanginita Chemicals Limited's (NSE:SANGINITA) Share Price Following 26% Dive

Sanginita Chemicals Limited (NSE:SANGINITA) Surges 38% Yet Its Low P/S Is No Reason For Excitement

Jan 02
Sanginita Chemicals Limited (NSE:SANGINITA) Surges 38% Yet Its Low P/S Is No Reason For Excitement

These 4 Measures Indicate That Sanginita Chemicals (NSE:SANGINITA) Is Using Debt Reasonably Well

Dec 30
These 4 Measures Indicate That Sanginita Chemicals (NSE:SANGINITA) Is Using Debt Reasonably Well

Sanginita Chemicals (NSE:SANGINITA) Seems To Use Debt Quite Sensibly

Sep 05
Sanginita Chemicals (NSE:SANGINITA) Seems To Use Debt Quite Sensibly

Is Sanginita Chemicals (NSE:SANGINITA) Using Too Much Debt?

Dec 13
Is Sanginita Chemicals (NSE:SANGINITA) Using Too Much Debt?

We Think Sanginita Chemicals (NSE:SANGINITA) Is Taking Some Risk With Its Debt

Feb 15
We Think Sanginita Chemicals (NSE:SANGINITA) Is Taking Some Risk With Its Debt

Sanginita Chemicals (NSE:SANGINITA) Has A Somewhat Strained Balance Sheet

Jul 22
Sanginita Chemicals (NSE:SANGINITA) Has A Somewhat Strained Balance Sheet

Is Sanginita Chemicals (NSE:SANGINITA) Using Too Much Debt?

Mar 16
Is Sanginita Chemicals (NSE:SANGINITA) Using Too Much Debt?

Sanginita Chemicals Limited's (NSE:SANGINITA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Jan 18
Sanginita Chemicals Limited's (NSE:SANGINITA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Does Sanginita Chemicals (NSE:SANGINITA) Have A Healthy Balance Sheet?

Nov 26
Does Sanginita Chemicals (NSE:SANGINITA) Have A Healthy Balance Sheet?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sanginita Chemicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:SANGINITA - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20231,32313N/AN/AN/A
9/30/20231,3671181102N/A
6/30/20231,3346N/AN/AN/A
3/31/20231,4864128137N/A
12/31/20221,5350N/AN/AN/A
9/30/20221,720-92629N/A
6/30/20221,918-3N/AN/AN/A
3/31/20221,9813-36-30N/A
12/31/20212,1277N/AN/AN/A
9/30/20211,977124753N/A
6/30/20211,95317N/AN/AN/A
3/31/20211,64888285N/A
12/31/20201,4866N/AN/AN/A
9/30/20201,567202224N/A
6/30/20201,46224N/AN/AN/A
3/31/20201,59834-24-16N/A
12/31/20191,64850N/AN/AN/A
9/30/20191,58944N/AN/AN/A
6/30/20191,74838N/AN/AN/A
3/31/20191,87639-36N/A
3/31/20181,945351728N/A
3/31/20171,47311N/A-74N/A
3/31/20161,44111N/A2N/A
3/31/20151,28610N/A23N/A
3/31/20141,1908N/A57N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von SANGINITA über der Sparquote liegt (6.7%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von SANGINITA schneller wachsen werden als der Markt Indian

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SANGINITA in den nächsten 3 Jahren signifikant steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SANGINITA schneller wachsen werden als der Markt von Indian.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von SANGINITA schneller wachsen werden als 20% pro Jahr.


Earnings per Share Growth Forecasts


Future Return on Equity

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SANGINITA in 3 Jahren voraussichtlich hoch sein wird


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.